Navigation Links
GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes
Date:12/11/2007

baseline risk for cardiovascular disease.

The use of rosiglitazone in this database does not reflect its use

among patients in the real world.

-- Patients prescribed rosiglitazone alone suffered from more chronic

diseases compared with those prescribed pioglitazone alone;

therefore they were sicker patients. However this difference is not

corrected for in the analysis of the data and in the study

conclusions.

-- The TZD monotherapy patient population in the ICES analysis had a

4-fold higher rate of kidney impairment, which is indicative of

patients with more progressive type 2 diabetes.

-- The authors state that the study may have been underpowered to detect

adverse effects associated with pioglitazone because of the relatively

small number of persons prescribed pioglitazone alone. It is stated

that larger studies are needed to better determine the relative

effect of each agent on cardiovascular outcomes.

-- The ICES analysis included insulin therapy within the TZD combination

group but excluded insulin combinations within the comparison group.

Insulin is known to be associated with increased CHF and cardiovascular

risk. Therefore, this biases the TZD combination group towards

increased cardiovascular risk relative to the comparison group. This

also permits more advanced patients, with poor glycemic control and who

are at greater risk of cardiovascular complications, to be included in

the TZD population while excluding them from the control group.

Avandia(R) (rosiglitazone maleate) is a widely studied oral anti-diabetic medicine for the treatment of type 2 diabetes, and importantly, Avandia has been shown to control blood sugar for longer than the most commonly used oral anti-diabetic medicines - up to five years. When used in the a
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
2. AUDIO from Medialink and GlaxoSmithKline: Fiber Key in Managing Irritable Bowel Syndrome (IBS) Symptoms
3. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
4. GlaxoSmithKline Awarded U.S. Department of Defense Contract to Pursue Novel Antibacterial Research Program
5. GlaxoSmithKline and Anacor Pharmaceuticals Form Alliance to Develop Systemic Antivirals and Antibiotics Based on Boron Chemistry
6. BioWa Announces Licensing of BioWas POTELLIGENT(R) Technology by GlaxoSmithkline for Use in Antibody Research and Development
7. GlaxoSmithKline Consumer Healthcare Recommends Maintaining FDAS Current Two-Class Drug System
8. ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information
9. Updated Drug Development Scrip Report Responds to the Pharma Industrys Major Changes
10. Michigan Catholic Conference Responds to Formation of Embryonic Stem Cell Research Ballot Committee
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... 2014 Cirrascale Corporation ®, ... and rackmount computing infrastructure, today announced it will ... throughout its GPU-enabled blade server and high-performance workstation ... latest proprietary 80-lane Gen3 PCIe switch-enabled risers, the ... K80 dual-GPU accelerator cards in a single blade, ...
(Date:11/18/2014)... 18, 2014 American Process Inc. ... formed a partnership with researchers at Georgia Institute ... Technology, and the USDA’s Forest Products Laboratory to ... nanocellulose. Nanocellulose is a rapidly emerging high performance ... project is to replace heavy steel structures within ...
(Date:11/18/2014)... Nov. 18, 2014 PDL BioPharma, Inc. (PDL) ... connection with the acquisition of Durata Therapeutics, Inc. by ... with the termination of PDL,s credit agreement with Durata, ... of $40 million, accrued interest, and prepayment and change ... a structured financing transaction with Durata in which PDL ...
(Date:11/17/2014)... The new METTLER TOLEDO White Paper " Traceability ... becoming the first calibration laboratory in the world ... the microgram range. National Metrology Institutes (NMI's), private ... in nanotechnology applications will benefit from understanding the ... weights in the range of 0.05 mg to ...
Breaking Biology Technology:Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 2Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 3American Process Inc. Announces Partnership to Develop Ultra-Strong, Lightweight Automotive Components Using Nanotechnology from Nature 2American Process Inc. Announces Partnership to Develop Ultra-Strong, Lightweight Automotive Components Using Nanotechnology from Nature 3PDL BioPharma Announces Successful Conclusion of Debt Financing Agreement with Durata Therapeutics 2New White Paper on Microgram Weights Describes How to Achieve Traceable Measurement Down to 0.05 Milligrams 2
... Jan. 31, 2011 Fox Chase Cancer Center , one ... the posting of clinical outcomes data to its website ... seek cancer care.  This initiative follows on a survey Fox Chase ... success rates as the factor that would be the most ...
... China-Biotics, Inc. ("China-Biotics", the "Company") (Nasdaq: ... of probiotics products in China, today announced it will ... p.m. Beijing Time on Wednesday, February 9, 2011, to ... for the period ended December 31, 2010. ...
... Mass., Jan. 31, 2011 Haemonetics Corporation (NYSE: HAE ... net income of $19.7 million, up 8%, and earnings per share ... third quarter net income was $ 22.6 million, up 21%, and ... revenue was up 6%, adjusted net income was up 21%, and ...
Cached Biology Technology:Fox Chase Cancer Center Publishes Clinical Outcomes for Patient Use 2Fox Chase Cancer Center Publishes Clinical Outcomes for Patient Use 3China-Biotics to Report Fiscal Year 2011 Third Quarter Financial Results on February 9 2Haemonetics Reports Third Quarter of Fiscal 11 2Haemonetics Reports Third Quarter of Fiscal 11 3Haemonetics Reports Third Quarter of Fiscal 11 4Haemonetics Reports Third Quarter of Fiscal 11 5Haemonetics Reports Third Quarter of Fiscal 11 6Haemonetics Reports Third Quarter of Fiscal 11 7Haemonetics Reports Third Quarter of Fiscal 11 8Haemonetics Reports Third Quarter of Fiscal 11 9Haemonetics Reports Third Quarter of Fiscal 11 10Haemonetics Reports Third Quarter of Fiscal 11 11Haemonetics Reports Third Quarter of Fiscal 11 12Haemonetics Reports Third Quarter of Fiscal 11 13
(Date:11/6/2014)... Baltimore, MD, November 6, 2014 - Insilico Medicine, ... in aging and age related diseases announced a ... medicine of cancer, Champions Oncology, Inc (OTC: CSBR). ... genomics for personalized medicine, but Champions Oncology,s TumorGraft ... can validate the chemotherapy regimen experimentally generating vast ...
(Date:11/5/2014)... RENO – Kelly Redmond has dedicated his career ... knowledge to a general audience. , As deputy ... Climate Center at Nevada,s Desert Research Institute, Redmond ... the management, application and dissemination of climate data ... Annual Fall Meeting in San Francisco on December ...
(Date:11/4/2014)... SALT LAKE CITY, Nov. 5, 2014 – University of ... uses enzymes to help jet fuel produce electricity without ... can be used to power portable electronics, off-grid power ... appears online today in the American Chemical Society journal ... into electricity through a chemical reaction between a fuel ...
Breaking Biology News(10 mins):Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2Nevada climatologist to be honored at AGU Fall Meeting for lifetime of public outreach 2Jet-fueled electricity at room temperature 2
... 2012 The Phoenix Community Alliance (PCA) will honor ... Institute (TGen), with its most prestigious award. Dr. ... Award for his work in improving the lives of ... such as Alzheimer,s, diabetes and many types of cancer. ...
... The National Institutes of Health has awarded The Scripps ... pathway in the development and maintenance of B-cell lymphoma, a ... normal disease fighting cells into cancers. The disease affects immune ... blood cells. John Cleveland, PhD, chair of the ...
... MD FASEB MARC (Maximizing Access to Research Careers) ... 2012 American Society for Clinical Investigation/Association of American Physicians ... 2012. These awards are meant to promote the ... the mainstream of the basic science community and to ...
Cached Biology News:Phoenix Community Alliance honors TGen's Dr. Jeffrey Trent 2Scientists win $2 million to study new pathway in development and maintenance of lymphoma 2
... configured specifically for pharmaceutical powder packaging, ... are precision-joined to create ultra-smooth surfaces ... and disinfect. One-inch radius corners simplify ... strong, rigid surface without external bracing. ...
... sensitive reagent for the detection of inorganic ... of recombinant E. coli phosphate-binding protein labeled ... to changes in its environment.How it worksBinding ... rapid and tight (Kd ~ 0.1 M), ...
... This benchtop ductless exhaust hood ... allowing safe indoor release of exhaust. ... contaminants. Over 28" of vertical clearance ... glassware. Includes polypropylene spill tray; options ...
... ideal modular cleanroom for biological safety ... require cleanliness (to Class 10/ISO 3) ... to create ultra-smooth surfaces that are ... One-inch radius corners simplify cleaning. Unique ...
Biology Products: